Cell-free dna methylation evaluation in patients with thyroid diseases

Basit Öğe Kaydı
dc.contributor.authorCilgin, Guner Begum
dc.contributor.authorCil, Ozge Caglar
dc.contributor.authorUslu, Atilla
dc.contributor.authorCayir, Akin
dc.date.accessioned2025-01-27T20:20:42Z
dc.date.available2025-01-27T20:20:42Z
dc.date.issued2022
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAim: The main aim of the study was to evaluate the DNA 5-methylcytosine (m5C) level, measured in circulating cell-free DNA (ccfDNA) as a distinct feature of thyroid gland-related disorders, including thyroiditis, benign nodule, and malignant nodule.Material and Methods: The study included 75 patients with 30 benign nodules, 30 thyroiditis, and 15 thyroid cancers; 19 subjects were evaluated as a control group. We collected peripheral blood samples from three disease groups and the controls, and then separated the plasma from the whole blood. We measured m5C in ccfDNA purified from plasma samples of patients and healthy individuals.Results: The level of m5C, measured in thyroiditis patients was significantly different from those measured in the control group, malignant and benign patients. We observed hypomethylation in benign and malignant patients when compared with the control group. However, there was no significant difference between the malignant patients and the control group and between the benign patients and the control group. After comparison of disease groups, we observed that there was no statistically significant difference between benign and malignant patients. We observed a statistically significant difference between thyroiditis and malignant patients (p<0.01) and between thyroiditis and benign patients (p=0.001).Discussion: Very few studies have reported that DNA methylation is an epigenetic mechanism in thyroiditis patients. Here, we reported that the level of m5C of ccfDNA could be used as a biomarker for thyroiditis. Further studies are required with the higher number of malign and benign patients to investigate the differences between patients with nodules and healthy individuals.
dc.description.sponsorshipCanakkale Onsekiz Mart University; Scientific Research Coordination Unit [TYL-2017-1114]
dc.description.sponsorshipThis work was supported by Canakkale Onsekiz Mart University, the Scientific Research Coordination Unit, Project number: TYL-2017-1114.
dc.identifier.doi10.4328/ACAM.21344
dc.identifier.endpage1353
dc.identifier.issn2667-663X
dc.identifier.issue12
dc.identifier.startpage1349
dc.identifier.urihttps://doi.org/10.4328/ACAM.21344
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21791
dc.identifier.volume13
dc.identifier.wosWOS:000895809100012
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherBayrakol Medical Publisher
dc.relation.ispartofAnnals of Clinical and Analytical Medicine
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectThyroid diseases
dc.subjectEpigenetic
dc.subjectDNA Methylation
dc.subjectCirculating Cell-Free DNA
dc.subjectCancer
dc.subjectThyroiditis
dc.titleCell-free dna methylation evaluation in patients with thyroid diseases
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu